Cognitive disorder, Schizophrenia research hub

An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia (CIAS)

This study is looking into a new medication called RL-007 to help people with schizophrenia improve their thinking, learning, and memory skills. It's a key step to see if RL-007 is safe and effective.